loading page

Comment on “ACE inhibitors and COVID-19: We don’t know yet”
  • Tevfik Ilcol,
  • Erkan Cure,
  • medine cumhur cure
Tevfik Ilcol
Ota&jinemed hospital
Author Profile
Erkan Cure
Ota&jinemed hospital
Author Profile
medine cumhur cure
Private practise
Author Profile

Peer review status:Published

01 May 2020Submitted to Journal of Cardiac Surgery
02 May 2020Assigned to Editor
02 May 2020Submission Checks Completed
02 May 2020Review(s) Completed, Editorial Evaluation Pending
02 May 2020Editorial Decision: Accept
Published in Cardiac Surgery volume 35 issue 6 on page 1387. Jun 2020. 10.1111/jocs.14647

Abstract

We read with great interest the article by Khashkhusha TR et al “ACE inhibitors and COVID-19: We don’t know yet”. The authors discuss whether the use of angiotensin-converting enzyme (ACE) inhibitors (ACEIs) in novel coronavirus disease‐19 (COVID‐19) patients is beneficial or harmful. ACEIs and angiotensin receptor antagonists (ARBs) both upregulate ACE2 levels. We believe that ARBs should be preferred since, unlike ARBs, ACEIs may increase angiotensin II through the chymase pathway. We would like to discuss potential harms ACEI may cause through secondary bradykinin-chymase pathways.